Drug intelligence / Profile preview

JCXH-221

Development stage: Phase 1
Lead developer: Immorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

JCXH-221 is a monovalent, broadly protective mRNA-based vaccine candidate developed for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine utilizes messenger RNA (mRNA) technology encapsulated in lipid nanoparticles (LNP), enabling delivery and expression of the encoded antigen in host cells to elicit an immune response. It is designed to provide broad protection against COVID-19 variants. The developer, Immorna Hangzhou Biotechnology, is focused on RNA-based therapeutics and vaccines. As of early 2025, JCXH-221 is in Phase II clinical development for COVID-19[1][2][3][6][7].

Beyond the preview

Go deeper on JCXH-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JCXH-221.

Explore the full profile